MoonLake Immunotherapeutics Class A Ordinary Shares
$12.46
$0.26 (+2.13%)
$11.88Day Range$12.51
Key Statistics
Market Cap
$1.04B
Shares Outstanding
85.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 6, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$12.29
Day High
$12.51
Day Low
$11.88
Volume
2.60M
VWAP
$12.25
Prev Close
$12.20
Transactions
--
Acc. Volume
--
About MoonLake Immunotherapeutics Class A Ordinary Shares
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
PHARMACEUTICAL PREPARATIONSSIC 2834130 employeesDORFSTRASSE 29, ZUG, V8, 630041 41 510 8022IPO Apr 6, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001821586
- Composite FIGI
- BBG00XQZQTS9
- Share Class FIGI
- BBG00XQZQVP7
- Ticker Root
- MLTX
- SIC Code
- 2834
About MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Stock
MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) closed the 2026-09-16 session at $12.46, up 2.13% versus the previous close (+0.26). The stock opened at $12.29 and traded between $11.88 and $12.51 during that session. Session trading volume was 2.6M shares. The volume-weighted average price (VWAP) is $12.25.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
MoonLake Immunotherapeutics Class A Ordinary Shares has a market capitalization of $1.04 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MLTX is listed on the XNAS exchange. The company employs approximately 130 people. MoonLake Immunotherapeutics Class A Ordinary Shares is headquartered in ZUG, V8. The recorded listing date is 2022-04-06.
On this page you can find market MLTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.